Diseases, Conditions, Syndromes

Gene variants protect against relapse after treatment for hepatitis C

Researchers at the Sahlgrenska Academy, University of Gothenburg, have identified a gene, which explains why certain patients with chronic hepatitis C do not experience relapse after treatment. The discovery may contribute ...

Oncology & Cancer

Developments in TACE and SIRT treatment in patients

Data from a number of clinical trials presented today at the International Liver Congress 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC).

Diseases, Conditions, Syndromes

Telaprevir: Added benefit in certain patients with hepatitis C

The drug telaprevir (trade name: Incivo) has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for ...

Diseases, Conditions, Syndromes

Boceprevir: Indication of added benefit for specific patients

The active ingredient boceprevir has been available since the middle of 2011 as a treatment for chronic hepatitis C of genotype 1. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal ...

Other

Changes to distribution of livers for transplant proposed

Transplantation specialists have proposed changes to the allocation and distribution of organs used for liver transplants. The recommended policy modifications take into account the scarcity of available organs, ensuring ...

page 9 from 10